ANDA 76175, held by Chartwell Rx. Mefloquine Hydrochloride.
As of Nov 16, 2026, ANDA 76175 (Mefloquine Hydrochloride), held by Chartwell Rx, was first approved by FDA on Feb 20, 2002, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 20, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mefloquine Hydrochloride250MG · tablet;oral | Mefloquine Hydrochloride | Rx |
| Oct 11, 2016 | Supplement 33Labeling · Standard review | Approved | None posted |
| Jul 26, 2013 | Supplement 30Labeling · Standard review | Approved | |
| Sep 2, 2011 | Supplement 26Labeling | Approved | |
| Oct 19, 2009 | Supplement 25Labeling | Approved | None posted |
| Jan 15, 2009 | Supplement 22Labeling | Approved | None posted |
| Sep 18, 2008 | Supplement 21Labeling | Approved | None posted |
| Apr 9, 2004 | Supplement 10Labeling | Approved | None posted |
| Oct 24, 2003 | Supplement 8Labeling | Approved | None posted |
| Oct 29, 2002 | Supplement 2Labeling | Approved | None posted |
| Feb 20, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters